Should a patient with gout continue hydrochlorothiazide (HCTZ) for hypertension?

HCTZ and Gout Management

Discontinue hydrochlorothiazide (HCTZ) in patients with gout and switch to an alternative antihypertensive agent, preferably losartan, which has uricosuric properties that can help lower serum uric acid levels.

The Problem with HCTZ in Gout

HCTZ directly precipitates hyperuricemia and gout through reduced renal uric acid secretion. The FDA label explicitly warns that "hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics" 1. This is not a theoretical concern—the risk is dose-dependent and clinically significant:

• HCTZ doses ≥25 mg/day increase the risk of initiating anti-gout therapy by 2-fold (adjusted RR 1.99,95% CI 1.21-3.26) 2
• When combined with other antihypertensives, this risk increases further (RR 2.29) 2
• The mechanism involves volume depletion and direct inhibition of uric acid secretion 3

Why Continuing HCTZ is Problematic

Even if you initiate urate-lowering therapy (ULT), continuing HCTZ creates a pharmacologic contradiction:

• Diuretic use necessitates higher allopurinol doses to achieve target uric acid reduction 4
• You're essentially treating a medication-induced problem with another medication while maintaining the causative agent
• This increases pill burden, cost, and potential for adverse effects from higher ULT doses

The Better Alternative: Losartan

Switch to losartan as your antihypertensive agent in patients with gout. Losartan is unique among angiotensin II receptor blockers:

• It is the only ARB with significant uricosuric properties 5
• When switched from other ARBs plus diuretic to losartan/HCTZ combination, serum uric acid decreased by 0.44 mg/dL (p=0.01) 6
• This uric acid reduction occurs without compromising blood pressure control 6
• Clinical guidelines specifically recommend losartan for hypertensive patients with gout 3, 5

Clinical Algorithm

For patients with gout currently on HCTZ:

1. Discontinue HCTZ immediately (unless there's a compelling indication like heart failure where diuretics are essential)

2. Switch to losartan as first-line alternative:

   • Start losartan 50 mg daily
   • Titrate to 100 mg daily if needed for BP control
   • Monitor BP at 1-2 weeks after switch

3. If additional BP control needed, add:

   • Calcium channel blocker (amlodipine 5-10 mg), or
   • ACE inhibitor (if not using losartan), or
   • Other non-diuretic agents

4. Initiate or optimize ULT per 2020 ACR guidelines:

   • Start allopurinol ≤100 mg/day (lower if CKD stage ≥3) 4
   • Titrate to achieve serum uric acid <6 mg/dL
   • Provide anti-inflammatory prophylaxis (colchicine, NSAIDs, or prednisone) for 3-6 months 4

Important Caveats

When you might need to keep a diuretic:

• Heart failure with volume overload (compelling indication)
• Resistant hypertension requiring triple therapy
• In these cases, consider chlorthalidone over HCTZ—though both increase gout risk similarly 7, chlorthalidone is more effective for BP control and cardiovascular outcomes 8

Avoid the trap of "low-dose HCTZ is safe":

• While doses <25 mg/day have lower metabolic side effects 9, they still increase gout risk 2
• Low-dose HCTZ (12.5-25 mg) is also less effective than other antihypertensive classes for BP reduction 8

If the patient is already on ULT:

• Removing HCTZ may allow dose reduction of allopurinol
• This reduces cost and potential for allopurinol hypersensitivity syndrome

Bottom Line

There is no good reason to continue HCTZ in a patient with gout when superior alternatives exist. Losartan provides equivalent or better BP control while actively helping manage hyperuricemia rather than exacerbating it 5, 6. The 2020 ACR guidelines emphasize treating the underlying hyperuricemia 4, and continuing a medication that works against this goal is counterproductive.